.png?v=8c6527571d76e5472f015e54a39d96e5)
Standing Strong on Ovarian Cancer Day
Standing Strong on Ovarian Cancer Day: ICON's Commitment to Advancing Care
Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatment. Globally, it is the eighth most common cancer in women, with nearly 350,000 new cases reported each year. Despite progress in oncology, survival outcomes remain tightly linked to the timing of diagnosis.
A Disease Often Detected Too Late
The stark reality of ovarian cancer is its silent progression. Symptoms like bloating, abdominal discomfort, and changes in appetite are vague and often attributed to less serious conditions. As a result, only about 20% of ovarian cancer cases are detected at an early stage. This delay in diagnosis has profound consequences: five-year survival rates can range from as high as 93% when caught early to just 31% when detected late.
This challenge underscores the need for both public awareness and research into better diagnostic tools. Biomarkers, imaging technology, and AI-driven screening methods are all areas of active investigation, but no standard screening method has yet been established for the general population. The lack of early detection tools remains one of the key barriers to improved survival rates.Hope on the Horizon
Fortunately, treatment options for ovarian cancer have expanded significantly in recent years. One of the most impactful developments has been the introduction of PARP inhibitors, which target cancer cells with BRCA mutations by interfering with their DNA repair mechanisms. Drugs such as olaparib and niraparib have brought real progress for patients with certain genetic profiles.
Martin noted, "Recent treatment advances have included PARP inhibitors, but there are many development programs looking at PD-1 inhibitor combinations and some Antibody Drug Conjugates (ADCs). One of our customers is particularly focused on immunotherapies and ADCs, so we are very excited to be part of their development program." Beyond PARP inhibitors, there is growing interest in immunotherapy and Antibody Drug Conjugates (ADCs). PD-1 and PD-L1 inhibitors, which help restore the immune system's ability to recognize and attack cancer cells, are currently being explored in combination with chemotherapy or targeted agents.ICON's Role in Advancing Research
At ICON, we are proud to contribute meaningfully to this evolving landscape. We are currently supporting development programs focused on immunotherapies and ADCs, working closely with leading biopharmaceutical sponsors. Our experience in oncology clinical trials—particularly in gynaecologic cancers—positions us as a key partner in the global fight against ovarian cancer. Martin emphasized, "ICON is highly engaged with the global Investigator community in gynaecologic/ovarian oncology research. We have made important contributions to 13 ovarian cancer studies where many patients from North America & EMEA have participated in our ovarian cancer trials." Collaborating with the World's Leading Cooperative Groups A cornerstone of our success is our close collaboration with respected research networks such as ENGOT (European Network for Gynaecological Oncological Trials) and GOG (Gynaecologic Oncology Group). These organizations are instrumental in running high-quality clinical trials and have been central to many of the advances in ovarian cancer care.
Martin shared, "ICON’s excellent delivery of ovarian cancer studies is strongly correlated with our engagement with co-operative groups, like ENGOT covering Spain, Italy, France, Czech Republic, UK, Israel or GOG covering USA and Canada. ICON is proud of our strong experience in engaging with these co-operative groups and the difference we are trying to bring to the lives of patients and their families." ENGOT brings together trial groups from multiple countries including Spain, Italy, France, the Czech Republic, the UK, and Israel, while GOG covers sites across the USA and Canada. Our long-standing partnerships with these groups help ensure that studies are executed efficiently and ethically, while staying deeply connected to local investigators and patients. By aligning with ENGOT and GOG, ICON facilitates research that is both global in scope and locally relevant. We are able to leverage these networks to streamline patient recruitment, support investigator engagement, and uphold the highest standards in data quality and patient safety.Why Our Work Matters
Every clinical trial represents more than data points. It represents a chance for a patient to access cutting-edge treatment, a family to find hope, and a community to move closer to a cure. At ICON, we never lose sight of the people behind the protocols. Our focus on collaboration, quality, and compassion drives our mission to improve patient outcomes.
We are especially proud of our efforts to foster inclusion in clinical trials, ensuring women from varied backgrounds and regions have access to potentially life-changing treatments. With every study we support, we strive to close the gap between medical research and the real-world needs of patients and caregivers.Looking to the Future
The fight against ovarian cancer is far from over, but progress is being made every day. Through our partnerships, scientific expertise, and unwavering dedication, ICON continues to push boundaries and make a meaningful difference in women’s health.
This Ovarian Cancer Day, we honour the courage of patients, the dedication of researchers, and the power of collaboration. We remain steadfast in our commitment to helping bring forward the next generation of therapies that will transform lives.Join Us in Making a Difference
Whether you are a clinician, researcher, or someone passionate about advancing healthcare, ICON offers opportunities to contribute to this important mission. Together, we can ensure that innovation reaches the women who need it most - faster, safer, and more effectively.
View our current job openings at ICON today.
Sign up for post alerts
ICON & You
The potential of together.
Careers that improve the lives of patients, our clients and each other. Are you ready to make a difference?
View jobsRelated jobs at ICON
Salary
Location
Korea, South
Department
Clinical Monitoring
Location
South Korea
Seoul
Remote Working
Office Based
Business Area
ICON Strategic Solutions
Job Categories
Clinical Monitoring
Job Type
Permanent
Description
Sr. CRA or CRA II, South Korea As a (Sr. CRA or CRA II) you will be joining the world’s largest & most comprehensive clinical research organisation, powered by healthcare intelligence. You will be par
Reference
2025-119732
Expiry date
01/01/0001
Author
Sonia OhAuthor
Sonia OhSalary
Location
United States
Department
Clinical Operations Roles
Location
United States
Remote Working
Remote
Business Area
ICON Strategic Solutions
Job Categories
Contracts Administration
Job Type
Permanent
Description
The Investigator Contracts Analyst is responsible for direct site-facing contract and budget negotiations thought contract execution with assigned clinical investigator sites including initial agreeme
Reference
2025-119740
Expiry date
01/01/0001
Author
Brandon PupekAuthor
Brandon PupekSalary
Location
United States
Department
Clinical Operations Roles
Location
United States
Remote Working
Remote
Business Area
ICON Strategic Solutions
Job Categories
Contracts Administration
Job Type
Permanent
Description
The Investigator Contracts Analyst is responsible for direct site-facing contract and budget negotiations thought contract execution with assigned clinical investigator sites including initial agreeme
Reference
2025-119738
Expiry date
01/01/0001
Author
Brandon PupekAuthor
Brandon PupekSalary
Location
United States
Department
Clinical Operations Roles
Location
United States
Remote Working
Remote
Business Area
ICON Strategic Solutions
Job Categories
Contracts Administration
Job Type
Permanent
Description
The Investigator Contracts Analyst is responsible for direct site-facing contract and budget negotiations thought contract execution with assigned clinical investigator sites including initial agreeme
Reference
2025-119737
Expiry date
01/01/0001
Author
Brandon PupekAuthor
Brandon PupekRelated stories
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/22/2025
Summary
World Schizophrenia Awareness Day 2025 Every year on 24 May, World Schizophrenia Awareness Day offers a vital opportunity to raise awareness, dismantle stigma, and celebrate the strength of individ
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/07/2025
Summary
Patient Centricity in Clinical Research: What it is and Why it Matters In the past, clinical research was designed around the needs of sponsors, researchers, and regulatory bodies. Patients were of
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/05/2025
Summary
Navigating Regulatory Landscapes: Comparing FDA, EMA, & MHRA in Clinical Trials In clinical research, no matter how promising a new therapy may be, it will go nowhere without regulatory appro
Recently viewed jobs
Impactful work. Meaningful careers. Quality rewards.
At ICON, our employees are our greatest strength. That’s why we are committed to empowering you to live your best life, both inside and outside of work. Whether your ambition is lead a global team, become a deep scientific or technical expert, work in-house with our customers or gain experience in a variety of different ICON functions, we will support you in realising your full potential. See all locations Learn more about Our Culture at ICON